Retatrudtide

Description

Retatrutide (LY3437943) is a novel long-acting peptide agonist targeting three incretin-related receptors: glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors. Developed by Eli Lilly, it is the first triple agonist of its class to enter advanced clinical investigation.The molecule features a 39-amino-acid sequence with a C20 fatty diacid moiety enabling albumin binding and extended half-life. Laboratory research has investigated its simultaneous activation of GLP-1R, GIPR, and GCGR signaling cascades, examining differential cAMP accumulation, beta- arrestin recruitment, and receptor internalization kinetics across all three receptor subtypes. In-vitro studies have characterized its binding affinity profile, with reported EC50 values in the picomolar to low nanomolar range across target receptors.Molecular Weight: 4,731.33 g/mol. Appearance: White lyophilized powder. Solubility: Soluble in bacteriostatic water. Storage: -20°C lyophilized, 2-8°C reconstituted. Reconstitute with BAC water slowly along the vial wall. Handle with care — avoid vigorous shaking.